Investigations into the mechanism of action of the antibacterial agent norfloxacin.
about
The fluoroquinolones: structures, mechanisms of action and resistance, and spectra of activity in vitroEffects of ciprofloxacin on eucaryotic pyrimidine nucleotide biosynthesis and cell growthAntibiotic treatment enhances the genome-wide mutation rate of target cellsA synergistic effect of artocarpanone from Artocarpus heterophyllus L. (Moraceae) on the antibacterial activity of selected antibiotics and cell membrane permeabilityTransport of pefloxacin across the bacterial cytoplasmic membrane in quinolone-susceptible Staphylococcus aureusCationic methacrylate polymers as topical antimicrobial agents against Staphylococcus aureus nasal colonizationIn vitro and in vivo antibacterial activities of T-3262, a new fluoroquinolone.Ofloxacin: its pharmacology, pharmacokinetics, and potential for clinical application.Quinolone resistance locus nfxD of Escherichia coli is a mutant allele of the parE gene encoding a subunit of topoisomerase IV.Mutants of Escherichia coli K-12 exhibiting reduced killing by both quinolone and beta-lactam antimicrobial agentsIn vitro cleavable-complex assay to monitor antimicrobial potency of quinolones.Association between early inhibition of DNA synthesis and the MICs and MBCs of carboxyquinolone antimicrobial agents for wild-type and mutant [gyrA nfxB(ompF) acrA] Escherichia coli K-12Isolation and characterization of an Escherichia coli strain exhibiting partial tolerance to quinolonesEffect of DNA gyrase inhibitors pefloxacin, five other quinolones, novobiocin, and clorobiocin on Escherichia coli topoisomerase I.Norfloxacin binds to human fecal materialAntimicrobial activity of ciprofloxacin against Pseudomonas aeruginosa, Escherichia coli, and Staphylococcus aureus determined by the killing curve method: antibiotic comparisons and synergistic interactions.Effects of norfloxacin on DNA metabolism in Pseudomonas aeruginosa.The mode of action of quinolones: the paradox in activity of low and high concentrations and activity in the anaerobic environment.Lytic effect of two fluoroquinolones, ofloxacin and pefloxacin, on Escherichia coli W7 and its consequences on peptidoglycan composition.Efficacy of levofloxacin in the treatment of BK viremia: a multicenter, double-blinded, randomized, placebo-controlled trialDrugs in development for tuberculosis.Development of levofloxacin inhalation solution to treat Pseudomonas aeruginosa in patients with cystic fibrosisCombined use of in vitro phototoxic assessments and cassette dosing pharmacokinetic study for phototoxicity characterization of fluoroquinolones.Ciprofloxacin: chemistry, mechanism of action, resistance, antimicrobial spectrum, pharmacokinetics, clinical trials, and adverse reactions.Mode of action, and in vitro and in vivo activities of the fluoroquinolones.Norfloxacin: clinical pharmacology and clinical use.Correlation of quinolone MIC and inhibition of DNA, RNA, and protein synthesis and induction of the SOS response in Escherichia coli.Accumulation of enoxacin by Escherichia coli and Bacillus subtilis.Possible physiological functions of penicillin-binding proteins in Staphylococcus aureus.Bacteriophage PSP3 and phi R73 activator proteins: analysis of promoter specificities.Evaluation of the in vitro bactericidal action of ciprofloxacin on cells of Escherichia coli in the logarithmic and stationary phases of growth.Inhibition of Micrococcus luteus DNA gyrase by norfloxacin and 10 other quinolone carboxylic acids.Genetic and biochemical characterization of norfloxacin resistance in Escherichia coli.Increased susceptibility of Pseudomonas aeruginosa to ciprofloxacin in the presence of vancomycin.Secondary bacterial infections and antibiotic resistance among tungiasis patients in Western, Kenya.In vitro antibacterial activity of AM-1155, a novel 6-fluoro-8-methoxy quinolone.Synergistic effect of artocarpin on antibacterial activity of some antibiotics against methicillin-resistant Staphylococcus aureus, Pseudomonas aeruginosa, and Escherichia coli.Bioequivalence evaluation of norfloxacin 400 mg tablets (Uroxin and Noroxin) in healthy human volunteers.Inappropriate breast secretions of possible bacterial etiology in the parous nonpuerperal female.Development of Pseudomonas aeruginosa resistance to norfloxacin during therapy.
P2860
Q24670241-C727C38A-E247-4E6B-A00B-3DCC623FDBBFQ24677043-0BAEBC83-3654-42E0-8CE9-373D5689D36DQ28386555-FFD2D60C-3B25-43BC-AF17-0BF8C97E6F9CQ33675580-DFE1CB26-1568-4771-BBB5-7B267AF6D183Q33745800-6E2DBAA2-0709-4C44-9DBC-22971E6C031CQ34033741-3387BE44-EB79-45B7-8544-3F0AAFD81FCEQ34681603-837C3430-65E1-4E40-B3D3-FFBC4217FC25Q34687048-81941F19-2DB0-4A74-AE31-85E3D6B75CEBQ35131579-08845C8B-B21E-40DB-865A-6E844C222792Q35277130-A776346D-E8A6-441C-AC15-A68852CBA603Q35314754-04D8BD6B-9482-40F6-BE09-4E5276833963Q35315975-DE73F96B-1866-41A3-9528-88F07BF3C42DQ35332818-55CB47E2-FFCC-45BF-A35D-D253AA5610F0Q35562756-3732324A-F6B7-4454-9D5E-7B51945B6DB1Q35566005-79DDDA8A-8C5C-4510-B686-997A09AA0B02Q35646442-95E720F9-5359-46C6-921A-C874EB14E03CQ35648233-B40F5846-E8FC-4149-A30D-87304E0ECA12Q36670132-864DE358-9FD8-4015-BCFE-A38494171A02Q36754157-0816B510-CAE9-422A-8C54-71AD140400C6Q37621540-E09C766C-7D06-422A-874D-9FADB7B17A65Q37809841-8EDD163A-D93C-4F12-A70E-DCF841624C8EQ38170953-E7E2E52E-C8E9-4E2A-9FA5-13050D2D73F8Q38254554-376DB1D4-0A31-4E98-BBFE-13F013B1A426Q39214819-A5E66D0A-0577-4ED0-AAF9-42E8F5892A8AQ39637667-1D417698-9BAB-4E8B-91B4-BB4CA9E23D2CQ39681144-3EEBDBE1-E440-4360-AFD1-15D6DC2EB46AQ39817311-339CAEDF-8AD4-4D74-9ADB-961EFD49F433Q39828684-37C87CDB-0254-41A6-ACE3-BE3D6ED69889Q39834475-EEF65306-F9C2-4B5B-9215-369AA856C824Q39842845-36D54A2A-10AD-4C18-BEBD-51B92063B530Q39850437-81214D11-A44C-4352-AEF0-1750E0FFFF2FQ39851068-ED129564-F27A-4831-9601-4CBECABFBFBDQ39851107-3D956061-E24C-4AAC-AA7B-1CD908419ED9Q39882590-535872C0-1358-4F63-9F03-AC283441AC87Q40060387-EFBB7E6B-031C-4C3D-9B2A-DC8468A23E23Q40285332-B1C0DB85-2FC1-4E44-9E7B-34A1EA0FD1EEQ50928904-2EE8391A-9380-49E8-A6B1-47C7DB4F49F2Q51551223-2C983DBF-2F38-4F8E-B3A5-DA5FCD061382Q52027867-35254B48-36C6-4139-996B-F76F65F83C1BQ54375847-EC307353-94FF-44AA-BEDD-A62CED2C4D41
P2860
Investigations into the mechanism of action of the antibacterial agent norfloxacin.
description
1984 nî lūn-bûn
@nan
1984年の論文
@ja
1984年論文
@yue
1984年論文
@zh-hant
1984年論文
@zh-hk
1984年論文
@zh-mo
1984年論文
@zh-tw
1984年论文
@wuu
1984年论文
@zh
1984年论文
@zh-cn
name
Investigations into the mechanism of action of the antibacterial agent norfloxacin.
@en
Investigations into the mechanism of action of the antibacterial agent norfloxacin.
@nl
type
label
Investigations into the mechanism of action of the antibacterial agent norfloxacin.
@en
Investigations into the mechanism of action of the antibacterial agent norfloxacin.
@nl
prefLabel
Investigations into the mechanism of action of the antibacterial agent norfloxacin.
@en
Investigations into the mechanism of action of the antibacterial agent norfloxacin.
@nl
P2093
P356
P1476
Investigations into the mechanism of action of the antibacterial agent norfloxacin.
@en
P2093
P356
10.1093/JAC/13.SUPPL_B.9
P407
P478
13 Suppl B
P577
1984-05-01T00:00:00Z